

# Our investments

## Healthcare



**BIOCLINICA**<sup>®</sup>  
SEE MORE CLEARLY

Technology-enabled services to clinical trials and pharmaceutical companies  
[www.bioclinica.com](http://www.bioclinica.com)

## Acquired

# October 2016

## HQ

# US

(global operations)



## How we are creating value

Operating across offices in the US, Europe and Asia, Bioclinica has a diverse customer base, with more than 400 clients, including the top 20 pharmaceutical and biotechnology companies. Cinven seeks to capitalise on the trend towards increased outsourcing by trial sponsors seeking to reduce the costs of clinical trials as well as shorten timescales and improve efficiencies through new technologies and services.

Our Healthcare and Portfolio teams have worked closely with management to develop and refine Bioclinica's strategy and VCP.

## Developments in 2016

Leveraging our experience in Medpace, a contract research organisation that we acquired in 2014, our Healthcare team had identified Bioclinica, a specialty provider of technology-enabled services to clinical trials, as an attractive opportunity nearly two years prior to our investment in 2016. As a result of our understanding of the sub-sector and our long-standing relationship with the CEO, we were able to pre-empt and execute the investment quickly.